Wednesday, March 7, 2012

For Cushing's: Tosoh Bioscience Launches the ST AIA-PACK DHEA-S Assay

Tosoh introduces the ST AIA-PACK DHEA-S Assay for use on Tosoh Automated Immunoassay Analyzers

South San Francisco, CA (PRWEB) March 06, 2012

Tosoh Bioscience, Inc. introduces the ST AIA-PACK DHEA-S assay for use on Tosoh automated immunoassay analyzers including the AIA-360, AIA-600 II, AIA-1800, AIA-2000 and the new AIA-900.

Utilizing Tosoh's unit dose test cup reagent technology, ST AIA-PACK DHEA-S has an assay time of approximately 20 minutes. Single, unitized test cups require no pre-mixing, no pre-measuring and no on-board refrigeration. Dry reagent format ensures 90 day calibration stability for minimal waste and cost effective testing. Test cups are bar-coded for easy identification and inventory management.

ST AIA-PACK DHEA-S is designed for In Vitro Diagnostic Use Only for the quantitative measurement of dehydroepiandrosterone sulfate (DHEA-S) in human serum, heparinized or EDTA plasma. DHEA-S is used for the diagnosis of various diseases of the adrenal cortex, and is especially useful for the differential diagnosis of Cushing's syndrome.

Concentrations of DHEA-S are often measured, along with other hormones such as FSH, LH, prolactin, estrogen, and testosterone, to help diagnose polycystic ovarian syndrome (PCOS) and to help rule out other causes of infertility, amenorrhea, and hirsutism. DHEA-S levels may be ordered to investigate and diagnose the cause of virilization in young girls and early (precocious) puberty in young boys.

ST AIA-PACK DHEA-S has been designed for a variety of clinical diagnostic applications including: Pediatric/Children's Hospitals, Endocrinologist, GP, Reproductive and Metabolic Clinics.

Tosoh Bioscience, Inc. (TBI) provides highly sophisticated diagnostic systems for immunoassay and HPLC testing to doctor's offices, hospitals and reference laboratories throughout the Americas. Based in South San Francisco, CA, TBI is a U.S. subsidiary of Tosoh Corporation which is headquartered in Tokyo, Japan. TBI is part of Tosoh Corporation's Bioscience Division.

 

For the original version on PRWeb visit: www.prweb.com/releases/prwebTosoh/DHEAS/prweb9248342.htm

Read more: http://www.sfgate.com/cgi-bin/article.cgi?f=/g/a/2012/03/06/prweb9248342.DTL#ixzz1oTaQcBBo